News & Updates

Secondary kidney stones: to remove or not?
Secondary kidney stones: to remove or not?
30 Sep 2022 byAudrey Abella

Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.

Secondary kidney stones: to remove or not?
30 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022 byStephen Padilla

Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.

Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
27 Sep 2022
Poor sleep quality may increase odds of erectile dysfunction
Poor sleep quality may increase odds of erectile dysfunction
26 Sep 2022

Sleep parameters are robust predictors of erectile dysfunction (ED), suggesting that poor sleep quality contributes to a greater likelihood of ED, reveals a study.

Poor sleep quality may increase odds of erectile dysfunction
26 Sep 2022
Mirabegron benefits men with OAB, erectile dysfunction
Mirabegron benefits men with OAB, erectile dysfunction
26 Sep 2022
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.

PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022